CY2051B1 - Hiv-3 retrovirus and its use - Google Patents

Hiv-3 retrovirus and its use

Info

Publication number
CY2051B1
CY2051B1 CY9802051A CY9802051A CY2051B1 CY 2051 B1 CY2051 B1 CY 2051B1 CY 9802051 A CY9802051 A CY 9802051A CY 9802051 A CY9802051 A CY 9802051A CY 2051 B1 CY2051 B1 CY 2051B1
Authority
CY
Cyprus
Prior art keywords
hiv
retrovirus
nucleic acid
acid sequence
region
Prior art date
Application number
CY9802051A
Other languages
English (en)
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8199044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2051(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of CY2051B1 publication Critical patent/CY2051B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CY9802051A 1988-06-09 1998-04-30 Hiv-3 retrovirus and its use CY2051B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88109200A EP0345375B1 (fr) 1988-06-09 1988-06-09 Rétrovirus HIV-3 et son utilisation

Publications (1)

Publication Number Publication Date
CY2051B1 true CY2051B1 (en) 1998-04-30

Family

ID=8199044

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9802051A CY2051B1 (en) 1988-06-09 1998-04-30 Hiv-3 retrovirus and its use

Country Status (10)

Country Link
US (7) US5304466A (fr)
EP (3) EP1369427A3 (fr)
JP (1) JP2882654B2 (fr)
AT (1) ATE120234T1 (fr)
AU (1) AU625970B2 (fr)
CY (1) CY2051B1 (fr)
DE (1) DE3853422T2 (fr)
DK (1) DK176078B1 (fr)
ES (1) ES2072853T3 (fr)
WO (1) WO1989012094A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364933A (en) 1986-03-03 1994-11-15 Institut Pasteur Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2)
EP1369427A3 (fr) * 1988-06-09 2004-05-12 Innogenetics N.V. Souches du retrovirus HIV-3 et leur utilisation
EP0494317B2 (fr) * 1990-06-15 2000-12-27 Innogenetics N.V. Le rétrovirus SIV cpz-ant et ses applications
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
ATE179716T1 (de) 1992-03-06 1999-05-15 Innogenetics Nv Verfahren zur bestimmung von peptiden, die immunologisch wichtigen epitopen von hcv zugehörig sind
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
DE59309207D1 (de) 1992-10-06 1999-01-21 Dade Behring Marburg Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
GB9410044D0 (en) * 1994-05-19 1994-07-06 Int Murex Tech Corp Assay
CN1651457B (zh) 1994-10-20 2010-07-28 巴斯德研究所 Hiv-1 o组(或亚组)逆转录病毒抗原的核苷酸序列
US5599662A (en) * 1995-02-17 1997-02-04 Hoffmann-La Roche Inc. Oliconucleotide primers and probes for the detection of HIV-1
EP0832113B1 (fr) * 1995-06-07 2004-05-19 Abbott Laboratories Peptides destines a la detection du vih-1
US5612473A (en) * 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
WO1998040744A1 (fr) † 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Procede de detection simultanee d'antigenes de vih et d'anticorps de vih
US5922533A (en) * 1997-08-15 1999-07-13 Abbott Laboratories Rapid assay for simultaneous detection and differentiation of antibodies to HIV groups
US6846905B2 (en) 1997-08-15 2005-01-25 Abbott Laboratories Antigen constructs useful in the detection and differentiation of antibodies to HIV
US7244570B2 (en) 1998-08-04 2007-07-17 Luminex Molecular Diagnostics, Inc. Methods and compositions for modulating “marginally indiscriminant” hybridizations
US6235479B1 (en) 1999-04-13 2001-05-22 Bio Merieux, Inc. Methods and devices for performing analysis of a nucleic acid sample
DE60041489D1 (de) * 1999-07-09 2009-03-19 Gen Probe Inc Nachweis von hiv-1 durch amplifizierung von nukleinsäuren
CA2391560A1 (fr) 1999-11-16 2001-05-25 Geneart Gmbh Gessellschaft Fur Angewandte Biotechnologie Genome de l'inter-sous-type vih-1 (c/b') et ses applications
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20040002063A1 (en) * 2002-05-16 2004-01-01 Medmira Inc. Rapid vaccinia antibody detection device, method and test kit
US7556814B2 (en) * 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
ES2528901T3 (es) 2007-10-22 2015-02-13 Amorphical Ltd. Carbonato de calcio amorfo estable que comprende aminoácidos fosforilados, péptidos fosforilados sintéticos y proteínas gastrolíticas
EP2550362B1 (fr) 2010-03-25 2017-01-04 Oregon Health&Science University Glycoprotéines du cmv et vecteurs recombinés
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
EP3069730A3 (fr) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
CN107921060A (zh) 2015-06-04 2018-04-17 艾玛菲克有限公司 用于吸入施用、舌下施用或含服施用的无定形碳酸钙的组合物
US11052108B2 (en) 2016-10-25 2021-07-06 Amorphical Ltd. Amorphous calcium carbonate for treating a leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217861A (en) * 1983-09-15 1993-06-08 Institut Pasteur Antigen of a human retrovirus, namely p18 protein of human immunodeficiency virus (HIV), compositions containing the antigen, a diagnostic method for detecting acquired immune deficiency syndrome (AIDS) and pre-AIDS and a kit therefor
DE122005000039I1 (de) * 1984-10-18 2006-02-23 Pasteur Institut DNS-Fragmente des GAG-Gens von LAV
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5066782A (en) * 1986-01-22 1991-11-19 Institut Pasteur Retrovirus capable of causing AIDS, means and method for detecting it in vitro
ATE47725T1 (de) * 1986-01-22 1989-11-15 Pasteur Institut Zum hervorrufen von aids geeigneter retrovirus vom typ hiv-2, sowie seine antigen- und nukleinsaeure-bestandteile.
US5030714A (en) * 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
SE8701765L (sv) * 1987-04-28 1988-10-29 Statens Bakteriologiska Lab Analysmetod och medel foer denna
EP1369427A3 (fr) * 1988-06-09 2004-05-12 Innogenetics N.V. Souches du retrovirus HIV-3 et leur utilisation

Also Published As

Publication number Publication date
JP2882654B2 (ja) 1999-04-12
EP0345375B1 (fr) 1995-03-22
US5858647A (en) 1999-01-12
US5795743A (en) 1998-08-18
DE3853422D1 (de) 1995-04-27
US5567603A (en) 1996-10-22
EP0345375A1 (fr) 1989-12-13
DK33190D0 (da) 1990-02-08
US6265200B1 (en) 2001-07-24
EP1369427A2 (fr) 2003-12-10
EP1369427A3 (fr) 2004-05-12
EP0657532B1 (fr) 2003-12-17
US20030039954A1 (en) 2003-02-27
AU3762889A (en) 1990-01-05
DK33190A (da) 1990-03-28
US6013484A (en) 2000-01-11
US5304466A (en) 1994-04-19
DE3853422T2 (de) 1995-10-26
JPH02504583A (ja) 1990-12-27
DK176078B1 (da) 2006-04-10
ATE120234T1 (de) 1995-04-15
ES2072853T3 (es) 1995-08-01
AU625970B2 (en) 1992-07-23
EP0657532A1 (fr) 1995-06-14
WO1989012094A1 (fr) 1989-12-14

Similar Documents

Publication Publication Date Title
CY2051B1 (en) Hiv-3 retrovirus and its use
Salminen et al. Full-length sequence of an Ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C
EP0752887A4 (fr) Virus d'immunodeficience de recombinaison de la variole
NO921969L (no) Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener
AU1225088A (en) Peptides having immunological properties 2-hiv-2
McGettigan et al. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector
CA2107732A1 (fr) Retrovirus du groupe vih et son utilisation
KR970701782A (ko) 생체내에서 유전자의 통합성 발현(Coordinate in vivo gene expression)
EP0278940A3 (fr) Antigènes de surface de virus de l'hépatite B et antigènes hybridés les contenant
EP0512017A1 (fr) Vaccins.
NZ333500A (en) Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV
NZ525751A (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
EP0342860A3 (fr) Nouvelle protéine, séquences contenant le gène de cette protéine, vecteurs, procédés de préparation et utilisation
KR940019314A (ko) 인체면역결핍 바이어스(hiv) 억제 안티센스 서열 및 그밖의 다른 뉴클레오타이드 서열을 함유하는 발현 작제물, 레트로바이러스성 벡터 및 이를 함유하는 재조합 레트로바이러스
DE60026199T2 (de) Synthetische Gene für gagpol und deren Verwendungen
JP2004509601A5 (fr)
DK0946731T3 (da) Ikke-M, ikke O HIV-1 stammer, fragmenter og anvendelser
Hejdeman et al. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy
US7713530B2 (en) HIV-1 subtype isolate regulatory/accessory genes, and modification and derivatives thereof
KR900702045A (ko) 천연 hiv gp 160의 제조방법
Bibollet-Ruche et al. Complete genome analysis of one of the earliest SIVcpz Ptt strains from Gabon (SIVcpzGAB2)
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.
Blancou et al. Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus
CA2408786A1 (fr) Vecteurs retroviraux comportant une structure renforcee de terminaison de transcription 3'
DK0592636T3 (da) Fremgangsmåde til fremstilling af en levedygtig cellekultur, der er inficeret med en med dissemineret sklerose forbundet vi